Cargando…
Exploiting Epigenetic Alterations in Prostate Cancer
Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant a...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454930/ https://www.ncbi.nlm.nih.gov/pubmed/28486411 http://dx.doi.org/10.3390/ijms18051017 |
_version_ | 1783240939450400768 |
---|---|
author | Baumgart, Simon J. Haendler, Bernard |
author_facet | Baumgart, Simon J. Haendler, Bernard |
author_sort | Baumgart, Simon J. |
collection | PubMed |
description | Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed. |
format | Online Article Text |
id | pubmed-5454930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54549302017-06-08 Exploiting Epigenetic Alterations in Prostate Cancer Baumgart, Simon J. Haendler, Bernard Int J Mol Sci Review Prostate cancer affects an increasing number of men worldwide and is a leading cause of cancer-associated deaths. Beside genetic mutations, many epigenetic alterations including DNA and histone modifications have been identified in clinical prostate tumor samples. They have been linked to aberrant activity of enzymes and reader proteins involved in these epigenetic processes, leading to the search for dedicated inhibitory compounds. In the wake of encouraging anti-tumor efficacy results in preclinical models, epigenetic modulators addressing different targets are now being tested in prostate cancer patients. In addition, the assessment of microRNAs as stratification biomarkers, and early clinical trials evaluating suppressor microRNAs as potential prostate cancer treatment are being discussed. MDPI 2017-05-09 /pmc/articles/PMC5454930/ /pubmed/28486411 http://dx.doi.org/10.3390/ijms18051017 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Baumgart, Simon J. Haendler, Bernard Exploiting Epigenetic Alterations in Prostate Cancer |
title | Exploiting Epigenetic Alterations in Prostate Cancer |
title_full | Exploiting Epigenetic Alterations in Prostate Cancer |
title_fullStr | Exploiting Epigenetic Alterations in Prostate Cancer |
title_full_unstemmed | Exploiting Epigenetic Alterations in Prostate Cancer |
title_short | Exploiting Epigenetic Alterations in Prostate Cancer |
title_sort | exploiting epigenetic alterations in prostate cancer |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454930/ https://www.ncbi.nlm.nih.gov/pubmed/28486411 http://dx.doi.org/10.3390/ijms18051017 |
work_keys_str_mv | AT baumgartsimonj exploitingepigeneticalterationsinprostatecancer AT haendlerbernard exploitingepigeneticalterationsinprostatecancer |